Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 7/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | ATF1 | P18846 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | WDR5 | P61964 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31148450 | 0.89 | PTPN11 (0.47) | MAPTPTPN11POLBBRAFRAB9A | |
| SCHEMBL25210578 | 0.89 | PTPN11 (0.45) | MAPTPTPN11POLBATF1NFKB1 | |
| SCHEMBL30422832 | 0.89 | MAPT (0.41) | MAPTPTPN11POLBATF1NFKB1 | |
| SCHEMBL25211482 | 0.89 | MAPT (0.41) | MAPTPTPN11POLBATF1NFKB1 | |
| Formic Acid SCHEMBL31148429 | 0.87 | ROCK2 (0.38) | MAPTPTPN11POLB | |
| Formic Acid SCHEMBL25417907 | 0.87 | HTT (0.47) | MAPTPTPN11POLBWDR5 | |
| Formic Acid SCHEMBL31148455 | 0.87 | HTT (0.47) | MAPTPTPN11POLBWDR5 | |
| Formic Acid SCHEMBL31148399 | 0.87 | PTPN11 (0.36) | MAPTPTPN11POLBWDR5 | |
| Formic Acid SCHEMBL31485475 | 0.87 | HTT (0.47) | MAPTPTPN11POLBWDR5 | |
| Formic Acid SCHEMBL31148466 | 0.87 | PTPN11 (0.36) | MAPTPTPN11POLBWDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122192-A1 | 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| CN-118748995-A | 5-Pyrimidine carboxamide derivatives and methods of use thereof | 亚根达医疗公司 | 2024-10-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122192-A1 | 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME | RTCB, NSUN2, PRPF19 | MAPT 4668/4885PTPN11 4344/4885POLB 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.